Skip to main content

Advertisement

SpringerLink
Log in

Industry–academia collaborations for biomarkers

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

Several types of collaboration are being pursued to identify, validate and apply new biomarkers. Here, we highlight examples of such initiatives and discuss the challenges, approaches to address these challenges and key factors for success.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wholley, D. The Biomarkers Consortium. Nat. Rev. Drug. Discov. 13, 791–792 (2014).

    Article  CAS  PubMed  Google Scholar 

  2. Stephenson, D. & Sauer, J. M. The Predictive Safety Testing Consortium and the Coalition Against Major Diseases. Nat. Rev. Drug. Discov. 13, 793–794 (2014).

    Article  CAS  PubMed  Google Scholar 

  3. Lessl, M. et al. Crowd sourcing in drug discovery. Nat. Rev. Drug. Discov. 10, 241–242 (2011).

    Article  CAS  PubMed  Google Scholar 

  4. Küffner, R. et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat. Biotech. 33, 51–57 (2015).

    Article  Google Scholar 

  5. Dorsch, H. et al. Grants4Targets — an open innovation initiative to foster drug discovery collaborations between academia and the pharmaceutical industry. Nat. Rev. Drug. Discov. 14, 74–76 (2015).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank T. Schlange, M. Lessl, H. Dorsch (all at Bayer, Germany), and H.-D. Volk (at the Berlin-Brandenburg Center for Regenerative Therapies, Charité, Berlin, Germany) for helpful discussions, and P. Carrigan for critical reading of the manuscript.

Author information

Authors and Affiliations

  1. Bayer Global Drug Discovery, Müllerstrasse 178, Berlin, 13353, Germany

    Khusru Asadullah, Andreas Busch & Matthias Gottwald

  2. Charité University Medicine Berlin, Charitéplatz 1, Berlin, 10117, Germany

    Khusru Asadullah, Petra Reinke & Lilla Landeck

  3. Potsdam General Hospital, Charlottenstrasse 72, Potsdam, 14467, Germany

    Lilla Landeck

Authors
  1. Khusru Asadullah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Busch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthias Gottwald
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Petra Reinke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lilla Landeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Khusru Asadullah.

Ethics declarations

Competing interests

L.L. and P.R. have no conflict of interest to declare. K.A., A.B. and M.G. are employees and shareholders of Bayer.

Supplementary information

Supplementary information S1 (table)

Examples of biomarker consortia supported by public funding in Europe and the United States (PDF 92 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Asadullah, K., Busch, A., Gottwald, M. et al. Industry–academia collaborations for biomarkers. Nat Rev Drug Discov 14, 805–806 (2015). https://doi.org/10.1038/nrd4727

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4727

  • Springer Nature Limited

This article is cited by

Search

Navigation